Authors
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Expert explains how to fully optimize EHRsRecent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.
Latest:
Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinomaThe exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
Latest:
Current and Emerging Treatment Landscape of mHSPCJack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Latest:
Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUCThe real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Amy E. Krambeck, MD, on what’s needed to improve safety, efficacy of HoLEP"I would also like us to be able to reliably use even smaller scopes, but keep them efficient," says Amy E. Krambeck, MD.
Latest:
Expert highlights the latest radiotherapy developments in prostate cancer“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.
Latest:
Physician Burnout: Assessing and addressing its impact on your family“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.
Latest:
Ava Saidian, MD, on improving female representation in bladder cancer trials“Women not only tend to present with more aggressive disease, but they also have a higher probability of having what we call variant histology, so non-urothelial carcinoma,” says Ava Saidian, MD.
Latest:
Expert gives advice on implementing Aquablation with the HYDROS Robotic System"For urologists that are interested in implementing Aquablation into their armamentarium, I am very envious, because anyone who is going to start doing Aquablation now is going to be using the HYDROS System," says Ravi Munver, MD.
Latest:
A physical therapist’s advice for men with post-prostatectomy incontinence"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT.
Latest:
Neoadjuvant sacituzumab govitecan shows efficacy but now has uncertain future role in bladder cancerNeoadjuvant therapy with sacituzumab govitecan demonstrated hypothesis generating complete responses following surgery with tolerable toxicity after a protocol amendment requiring a dose reduction and G-CSF prophylaxis for patients with muscle-invasive bladder cancer.
Latest:
Malpractice Consult: Affidavits of merit and why they matterMost states require affidavits for malpractice cases to proceed.
Latest:
Perry Xu, MD, on the potential of AI in the endourology space“I think we can really use AI in several different facets of endourology," says Perry Xu, MD.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Justin Dubin, MD, on how direct-to-consumer men’s health companies can benefit patients"DTC companies, especially in the men's health space, have really done a wonderful job of destigmatizing conversations," says Justin Dubin, MD.
Latest:
EP. 4B: The Effect of Leuprolide Formulations on Organizational Management Practices in Metastatic Prostate CancerIn this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
Latest:
Quiz: Testicular trauma in 21-year-oldA 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.
Latest:
Expert emphasizes significance of physician self-careIf you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Latest:
A urologist on why the time is right to let go"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC“We found that the median rPFS with the combo of mevrometostat plus enzalutamide was 14.3 months, which compared favorably with what we saw with the enzalutamide arm, where the median was only 6.2 months,” says Michael Schweizer, MD.
Latest:
Experts consider efficacy of fertility restoration vs sperm cryopreservation“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it's at least as good,” says Scott D. Lundy, MD, PhD, HCLD.
Latest:
Extended lymphadenectomy yields no additional benefit vs standard procedure for urothelial cancerExtended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
